LMR Partners LLP Invests $1.59 Million in 10x Genomics, Inc. (NASDAQ:TXG)

LMR Partners LLP acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 70,303 shares of the company's stock, valued at approximately $1,587,000. LMR Partners LLP owned 0.06% of 10x Genomics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in 10x Genomics by 113.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company's stock valued at $26,000 after buying an additional 371 shares in the last quarter. First Horizon Advisors Inc. boosted its position in 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock worth $37,000 after purchasing an additional 808 shares during the period. Covestor Ltd boosted its position in 10x Genomics by 501.7% during the 1st quarter. Covestor Ltd now owns 1,047 shares of the company's stock worth $39,000 after purchasing an additional 873 shares during the period. KBC Group NV increased its holdings in 10x Genomics by 38.8% in the 3rd quarter. KBC Group NV now owns 3,225 shares of the company's stock valued at $73,000 after purchasing an additional 902 shares in the last quarter. Finally, Blue Trust Inc. raised its position in 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock valued at $40,000 after purchasing an additional 1,025 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Justin J. Mcanear sold 2,961 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $66,711.33. Following the completion of the transaction, the chief financial officer now directly owns 143,242 shares of the company's stock, valued at $3,227,242.26. This represents a 2.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the sale, the insider now directly owns 345,704 shares in the company, valued at $7,788,711.12. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,061 shares of company stock valued at $316,794. Insiders own 10.03% of the company's stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG traded up $0.39 during trading on Tuesday, reaching $13.57. The stock had a trading volume of 1,758,413 shares, compared to its average volume of 1,729,653. The firm's 50 day moving average price is $18.25 and its two-hundred day moving average price is $20.26. 10x Genomics, Inc. has a one year low of $12.95 and a one year high of $57.90. The stock has a market cap of $1.64 billion, a PE ratio of -8.61 and a beta of 1.87.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. During the same quarter in the prior year, the firm earned ($0.51) EPS. The company's revenue for the quarter was down 1.3% compared to the same quarter last year. On average, research analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

Analyst Ratings Changes

TXG has been the subject of several analyst reports. Canaccord Genuity Group decreased their target price on 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, October 10th. Barclays decreased their price target on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Stephens restated an "overweight" rating and issued a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. Finally, Leerink Partners initiated coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They set an "outperform" rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, 10x Genomics presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.19.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.